Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mesoblast

11.69
-0.0800-0.68%
Volume:98.47K
Turnover:1.15M
Market Cap:1.49B
PE:-12.67
High:11.85
Open:11.71
Low:11.61
Close:11.77
Loading ...

BRIEF-Mesoblast Says HY Loss Attributable $47.9 Million

Reuters
·
27 Feb

Mesoblast H1 2025 EPADS $(4.20) Down From $(3.72) YoY; Revenue $3.156M Down From $3.388M YoY

Benzinga
·
27 Feb

Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Dow Jones
·
27 Feb

Mesoblast Widens Fiscal H1 Loss as Revenue Drops

MT Newswires Live
·
27 Feb

Mesoblast Posts Fiscal H1 Loss of $0.042 Per Share, Revenue of $3.2 Million

MT Newswires Live
·
27 Feb

Mesoblast Ltd - Hy Loss Attributable $47.9 Mln

THOMSON REUTERS
·
27 Feb

Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks
·
26 Feb

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire
·
26 Feb

Mesoblast Ltd expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
25 Feb

Mesoblast Limited Announces New Director Appointment

TIPRANKS
·
24 Feb

Mesoblast Appoints Dr. Gregory George to Board, Strengthening Operational Expertise

TIPRANKS
·
24 Feb

Dr. Gregory George MD PhD Joins Mesoblast Board

GlobeNewswire
·
24 Feb

Mesoblast’s Ryoncil® Gains FDA Approval, Set to Revolutionize SR-aGvHD Treatment

TIPRANKS
·
14 Feb

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

Simply Wall St.
·
12 Feb

Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says

MT Newswires Live
·
12 Feb

Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?

Insider Monkey
·
12 Feb

Mesoblast Price Target Raised to $24.00/Share From $15.00 by Piper Sandler

Dow Jones
·
07 Feb

Mesoblast price target raised to $24 from $15 at Piper Sandler

TIPRANKS
·
07 Feb

Mesoblast's Largest Shareholder Raises Stake to Over 19%; Mesoblast Shares Up 3%

MT Newswires Live
·
07 Feb

BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares

Reuters
·
06 Feb